{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T18:30:42Z","timestamp":1735583442067},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,5,15]],"date-time":"2015-05-15T00:00:00Z","timestamp":1431648000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s10549-015-3417-0","type":"journal-article","created":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T08:34:34Z","timestamp":1431592474000},"page":"661-669","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Digoxin use after diagnosis of breast cancer and survival: a population-based cohort study"],"prefix":"10.1007","volume":"151","author":[{"given":"Reema A.","family":"Karasneh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam J.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00dana C.","family":"Mc Menamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmel M.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris R.","family":"Cardwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,15]]},"reference":[{"key":"3417_CR1","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1158\/1078-0432.CCR-11-1389","volume":"18","author":"RJ Biggar","year":"2012","unstructured":"Biggar RJ (2012) Molecular pathways: digoxin use and estrogen-sensitive cancers\u2014risks and possible therapeutic implications. Clin Cancer Res 18:2133\u20132137. doi: 10.1158\/1078-0432.CCR-11-1389","journal-title":"Clin Cancer Res"},{"key":"3417_CR2","volume-title":"British national formulary","author":"British Medical Association and the Royal Pharmaceutical Society of Great Britain","year":"2014","unstructured":"British Medical Association and the Royal Pharmaceutical Society of Great Britain (2014) British national formulary, 68th edn. Pharmaceutical Press, London","edition":"68"},{"key":"3417_CR3","doi-asserted-by":"crossref","first-page":"c1579","DOI":"10.1136\/bmj.c1579","volume":"340","author":"D Meerkotter","year":"2010","unstructured":"Meerkotter D, Patrick A (2010) Evaluation of breast masses in male patients. BMJ 340:c1579. doi: 10.1136\/bmj.c1579","journal-title":"BMJ"},{"key":"3417_CR4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/ijc.26424","volume":"131","author":"RJ Biggar","year":"2012","unstructured":"Biggar RJ, Wohlfahrt J, Melbye M (2012) Digoxin use and the risk of cancers of the corpus uteri, ovary and cervix. Int J Cancer 131:716\u2013721. doi: 10.1002\/ijc.26424","journal-title":"Int J Cancer"},{"key":"3417_CR5","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","volume":"310","author":"JE Manson","year":"2013","unstructured":"Manson JE, Chlebowski RT, Stefanick ML et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials. JAMA 310:1353\u20131368. doi: 10.1001\/jama.2013.278040","journal-title":"JAMA"},{"key":"3417_CR6","author":"V Beral","year":"2011","unstructured":"Beral V, Reeves G, Bull D et al (2011) Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. doi: 10.1093\/jnci\/djq527","journal-title":"J Natl Cancer Inst"},{"key":"3417_CR7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10549-014-2886-x","volume":"144","author":"TP Ahern","year":"2014","unstructured":"Ahern TP, Tamimi RM, Rosner BA, Hankinson SE (2014) Digoxin use and risk of invasive breast cancer: evidence from the Nurses\u2019 Health Study and meta-analysis. Breast Cancer Res Treat 144:427\u2013435. doi: 10.1007\/s10549-014-2886-x","journal-title":"Breast Cancer Res Treat"},{"key":"3417_CR8","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2010.32.8146","volume":"29","author":"RJ Biggar","year":"2011","unstructured":"Biggar RJ, Wohlfahrt J, Oudin A et al (2011) Digoxin use and the risk of breast cancer in women. J Clin Oncol 29:2165\u20132170. doi: 10.1200\/JCO.2010.32.8146","journal-title":"J Clin Oncol"},{"key":"3417_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/onci.23082","volume":"2","author":"L Menger","year":"2013","unstructured":"Menger L, Vacchelli E, Kepp O et al (2013) Trial watch: c ardiac glycosides and cancer therapy. Oncoimmunology 2:1\u20137","journal-title":"Oncoimmunology"},{"key":"3417_CR10","doi-asserted-by":"crossref","first-page":"R102","DOI":"10.1186\/bcr2205","volume":"10","author":"TP Ahern","year":"2008","unstructured":"Ahern TP, Lash TL, S\u00f8rensen HT, Pedersen L (2008) Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res 10:R102. doi: 10.1186\/bcr2205","journal-title":"Breast Cancer Res"},{"key":"3417_CR11","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr3386","volume":"15","author":"RJ Biggar","year":"2013","unstructured":"Biggar RJ, Andersen EW, Kroman N et al (2013) Breast cancer in women using digoxin: tumor characteristics and relapse risk. Breast Cancer Res 15:R13. doi: 10.1186\/bcr3386","journal-title":"Breast Cancer Res"},{"key":"3417_CR12","first-page":"493","volume":"6","author":"B Stenkvist","year":"1999","unstructured":"Stenkvist B (1999) Is digitalis a therapy for breast carcinoma? Oncol Rep 6:493\u2013496","journal-title":"Oncol Rep"},{"key":"3417_CR13","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/bmj.302.6779.766","volume":"302","author":"H Jick","year":"1991","unstructured":"Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 302:766\u2013768. doi: 10.1136\/bmj.302.6779.766","journal-title":"BMJ"},{"key":"3417_CR14","unstructured":"World Health Organization (2015) World Health Organization collaborating center for drug statistics methodology. http:\/\/www.whocc.no\/ . Accessed 16 Feb 2015"},{"key":"3417_CR15","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","volume":"340","author":"LE L\u00e9vesque","year":"2010","unstructured":"L\u00e9vesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340:b5087. doi: 10.1136\/bmj.b5087","journal-title":"BMJ"},{"key":"3417_CR16","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/jnci\/djt211","volume":"105","author":"J Chubak","year":"2013","unstructured":"Chubak J, Boudreau DM, Wirtz HS et al (2013) Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst 105:1456\u20131462. doi: 10.1093\/jnci\/djt211","journal-title":"J Natl Cancer Inst"},{"key":"3417_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2296-11-1","volume":"11","author":"NF Khan","year":"2010","unstructured":"Khan NF, Perera R, Harper S, Rose PW (2010) Adaptation and validation of the Charlson index for Read\/OXMIS coded databases. BMC Fam Pract 11:1. doi: 10.1186\/1471-2296-11-1","journal-title":"BMC Fam Pract"},{"key":"3417_CR18","unstructured":"Noble M, Wright G, Dibben C et al (2004) Indices of deprivation 2004: Report to the office of the deputy prime minister"},{"key":"3417_CR19","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/aje\/kwi307","volume":"162","author":"Z Zhou","year":"2005","unstructured":"Zhou Z, Rahme E, Abrahamowicz M, Pilote L (2005) Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 162:1016\u20131023. doi: 10.1093\/aje\/kwi307","journal-title":"Am J Epidemiol"},{"key":"3417_CR20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(79)90996-6","volume":"1","author":"B Stenkvist","year":"1979","unstructured":"Stenkvist B, Bengtsson E, Eriksson O et al (1979) Cardiac glycosides and breast cancer. Lancet 1:563","journal-title":"Lancet"},{"key":"3417_CR21","first-page":"49","volume":"2","author":"B Stenkvist","year":"1980","unstructured":"Stenkvist B, Bengtsson E, Eklund G et al (1980) Evidence of a modifying influence of heart glucosides on the development of breast cancer. Anal Quant Cytol 2:49\u201354","journal-title":"Anal Quant Cytol"},{"key":"3417_CR22","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1248\/bpb.29.1493","volume":"29","author":"K Bielawski","year":"2006","unstructured":"Bielawski K, Winnicka K, Bielawska A (2006) Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol Pharm Bull 29:1493\u20131497. doi: 10.1248\/bpb.29.1493","journal-title":"Biol Pharm Bull"},{"key":"3417_CR23","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1248\/bpb.31.1131","volume":"31","author":"K Winnicka","year":"2008","unstructured":"Winnicka K, Bielawski K, Bielawska A, Surazy\u0144ski A (2008) Antiproliferative activity of derivatives of ouabain, digoxin and proscillaridin A in human MCF-7 and MDA-MB-231 breast cancer cells. Biol Pharm Bull 31:1131\u20131140. doi: 10.1248\/bpb.31.1131","journal-title":"Biol Pharm Bull"},{"key":"3417_CR24","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ije\/dyp392","volume":"39","author":"D Sarfati","year":"2010","unstructured":"Sarfati D, Blakely T, Pearce N (2010) Measuring cancer survival in populations: relative survival vs cancer-specific survival. Int J Epidemiol 39:598\u2013610. doi: 10.1093\/ije\/dyp392","journal-title":"Int J Epidemiol"},{"key":"3417_CR25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0002-9343(02)01253-6","volume":"113","author":"H Vidaillet","year":"2002","unstructured":"Vidaillet H, Granada JF, Chyou P et al (2002) A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 113:365\u2013370","journal-title":"Am J Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3417-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-015-3417-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3417-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:43:13Z","timestamp":1559234593000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-015-3417-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,15]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["3417"],"URL":"https:\/\/doi.org\/10.1007\/s10549-015-3417-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,15]]}}}